160 related articles for article (PubMed ID: 27551115)
1. Perils of the Pathologic Complete Response.
Rose BS; Winer EP; Mamon HJ
J Clin Oncol; 2016 Nov; 34(33):3959-3962. PubMed ID: 27551115
[No Abstract] [Full Text] [Related]
2. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
A'Hern RP
J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
[No Abstract] [Full Text] [Related]
3. Outcomes and endpoints in cancer trials: bridging the divide.
Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MK; Sydes MR; Tannock IF; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e43-52. PubMed ID: 25638556
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
5. Cancer concepts and principles: primer for the interventional oncologist-part I.
Hickey R; Vouche M; Sze DY; Hohlastos E; Collins J; Schirmang T; Memon K; Ryu RK; Sato K; Chen R; Gupta R; Resnick S; Carr J; Chrisman HB; Nemcek AA; Vogelzang RL; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1157-64. PubMed ID: 23809510
[TBL] [Abstract][Full Text] [Related]
6. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
Saad ED; Buyse M
J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092
[No Abstract] [Full Text] [Related]
7. Novel approaches to composite endpoints in clinical trials.
Westerhout CM; Bakal JA
EuroIntervention; 2015 May; 11(1):122-4. PubMed ID: 25982656
[No Abstract] [Full Text] [Related]
8. Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
Mietlowski W; Wang J
Contemp Clin Trials; 2007 Sep; 28(5):674. PubMed ID: 17449334
[No Abstract] [Full Text] [Related]
9. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
11. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
12. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Aprile G; Fontanella C; Bonotto M; Rihawi K; Lutrino SE; Ferrari L; Casagrande M; Ongaro E; Berretta M; Avallone A; Rosati G; Giuliani F; Fasola G
Oncotarget; 2015 Oct; 6(30):28716-30. PubMed ID: 26308250
[TBL] [Abstract][Full Text] [Related]
13. Pathology is a necessary and informative tool in oncology clinical trials.
Nagtegaal ID; West NP; van Krieken JH; Quirke P
J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
[TBL] [Abstract][Full Text] [Related]
14. Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.
Markman M
Curr Oncol Rep; 2007 May; 9(3):159-60. PubMed ID: 17430685
[No Abstract] [Full Text] [Related]
15. Trial design in psoriatic arthritis: what could be changed?
Kavanaugh A; Boyd T
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S15-8. PubMed ID: 26458015
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials, End Points, and Statistics-Measuring and Comparing Cancer Treatments in Practice.
West H; Dahlberg S
JAMA Oncol; 2018 Dec; 4(12):1798. PubMed ID: 30193254
[No Abstract] [Full Text] [Related]
17. Metastatic disease response to treatment: how many lesions to measure?
Prassopoulos P; Mantatzis M
J Clin Oncol; 2010 Feb; 28(5):e81; author reply 82. PubMed ID: 19841318
[No Abstract] [Full Text] [Related]
18. Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
Harrison ML; Gore ME; Spriggs D; Kaye S; Iasonos A; Hensley M; Aghajanian C; Venkatraman E; Sabbatini P
Gynecol Oncol; 2007 Sep; 106(3):469-75. PubMed ID: 17614127
[TBL] [Abstract][Full Text] [Related]
19. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
20. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.
Wells AU; Behr J; Costabel U; Cottin V; Poletti V; Richeldi L;
Thorax; 2012 Nov; 67(11):938-40. PubMed ID: 23047830
[No Abstract] [Full Text] [Related]
[Next] [New Search]
